2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-N-(1,10-phenanthrolin-5-yl)isoindoline-5-carboxamide

Catalog No.: 
ACXQIK532
CAS No.: 
-
Molecular Formula: 
C26H17N5O5
Molecular Weight: 
479.45
2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-N-(1,10-phenanthrolin-5-yl)isoindoline-5-carboxamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$350.00In stock1 week
250mg95%$700.00In stock1 week
1g95%$1379.00In stock1 week

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-N-(1,10-phenanthrolin-5-yl)isoindoline-5-carboxamide
IUPAC Name2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-N-(1,10-phenanthrolin-5-yl)isoindoline-5-carboxamide
Molecular FormulaC26H17N5O5
Molecular Weight479.45
SMILESO=C1CCC(N2C(=O)C3=CC=C(C(=O)NC4=CC5=CC=CN=C5C5=NC=CC=C45)C=C3C2=O)C(=O)N1
InChI KeyVVXUPKUSGBAICS-UHFFFAOYSA-N

Synthetic Route by SureRoute

1. ACXQIK532 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACJKZN683 route compound structure diagram
    ACJKZN68354258-41-2 In Stock
  2. Plus
  3. ACSBOW273 route compound structure diagram
    ACSBOW2731216805-11-6 In Stock
  4. Then
  5. ACXQIK532 route product structure diagram
    ACXQIK532- In Stock
Inquiry

2. ACXQIK532 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACJKZN683 route compound structure diagram
    ACJKZN68354258-41-2 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACXQIK532 route product structure diagram
    ACXQIK532- In Stock
Inquiry

3. ACXQIK532 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACJKZN683 route compound structure diagram
    ACJKZN68354258-41-2 In Stock
  2. Plus
  3. ACSBOW273 route compound structure diagram
    ACSBOW2731216805-11-6 In Stock
  4. Then
  5. ACXQIK532 route product structure diagram
    ACXQIK532- In Stock
Inquiry

Comments (0)